Farshid Dayyani, MD, PhD, Discusses Multidisciplinary Approach to Research on Treatment for Gastroesophageal Adenocarcinoma

A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.

Farshid Dayyani, MD, PhD, of UC Irvine Health, spoke with CancerNetwork® about what multidisciplinary oncology professionals should know about a prospective, open-label, phase 2 trial (NCT04074343) examining the combination of cabozantinib (Cabometyx) with pembrolizumab (Keytruda) to overcome checkpoint inhibitor resistance for patients with metastatic or recurrent gastric and gastroesophageal adenocarcinoma.


The main early finding we had from this study is, because this is a single institution trial, that there’s a lot of interest. And we were getting a number of referrals from physicians in the community, from surgeons, and [from] gastroenterologists who hear about the study on clinicaltrials.gov or other sources and refer their patients to us. In that sense, we’ve been very fortunate to contribute to offering a new trial option to patients in Southern California and beyond. Actually, we have had patients from New York, as well.